Up-regulated DDX39 in Adrenocortical Carcinoma Is Associated With Patient Survival
Anticancer Research · 2025
DOI: 10.21873/anticanres.17469 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Yoshiatsu Tanaka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Research Promotion Centre, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan. Hauptthemen laut MEDLINE: DEAD-box RNA Helicases, Adrenocortical Carcinoma, Adrenal Cortex Neoplasms, Biomarkers, Tumor.
Abstract (Originalsprache)
BACKGROUND/AIM: Adrenocortical carcinoma is a very rare tumor characterized by poor prognosis and high mortality. The origin of this tumor is primarily the adrenal cortex. The 5-year overall survival rate of patients with adrenocortical carcinoma has not improved despite therapeutic advances. Early detection of this malignancy remains difficult, and no standard curative therapy currently exists. Therefore, it is important to understand the biology of adrenocortical carcinoma, and to identify prognostic biomarkers and molecular targets for its therapy. DDX39 is an Asp-Glu-Ala-Asp (DEAD)-box RNA helicase, which is required for transcription, splicing and transport of mRNA. There are some reports about overexpression of DDX39 in tumor tissues and cells (lung squamous cell cancer, gastrointestinal stromal tumor, urinary bladder cancer, malignant pleural mesothelioma). However, the clinicopathological involvement of DDX39 in adrenocortical carcinoma has not yet been documented. MATERIALS AND METHODS: The GEPIA, GEPIA2, and UALCAN platforms were used to analyze DDX39 mRNA expression and survival in patients with adrenocortical carcinoma. RESULTS: DDX39 was found to be significantly up-regulated in adrenocortical carcinoma tissues, and this up-regulation inversely correlated with prolonged patient survival. CONCLUSION: DDX39 may be a potential prognostic biomarker in patients with adrenocortical carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Research Promotion Centre, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
- Graduate School of Health and Welfare, Yamaguchi Prefectural University, Yamaguchi, Japan.
- Division of Oral and Maxillofacial Surgery School of Dentistry, and Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
- Advanced Research Promotion Centre, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan climates@hoku-iryo-u.ac.jp.
- School of Medical Technology, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Zitieren
APA
Tanaka, Y., Yamashita, S. N., Islam, S., Kitagawa, T., Tokuda, K., Paudel, D., Giri, S., Ohta, T., Harada, F., Nagayasu, H., & Kuramitsu, Y. (2025). Up-regulated DDX39 in Adrenocortical Carcinoma Is Associated With Patient Survival. Anticancer Research. https://doi.org/10.21873/anticanres.17469
Vancouver
Tanaka Y, Yamashita SN, Islam S, Kitagawa T, Tokuda K, Paudel D, et al. Up-regulated DDX39 in Adrenocortical Carcinoma Is Associated With Patient Survival. Anticancer Research. 2025. doi:10.21873/anticanres.17469
BibTeX
@article{Tanaka2025,
author = {Tanaka, Yoshiatsu and Yamashita, Shin-Nosuke and Islam, Shajedul and Kitagawa, Takao and Tokuda, Kazuhiro and Paudel, Durga and Giri, Sarita and Ohta, Tohru and Harada, Fumiya and Nagayasu, Hiroki and Kuramitsu, Yasuhiro},
title = {Up-regulated DDX39 in Adrenocortical Carcinoma Is Associated With Patient Survival},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17469}
}
EUVIMED